Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.

De Girolamo, L., Lucarelli, E., Alessandri, G., Avanzini, M. A., Bernardo, M. E., Biagi, E., Brini, A. T., D'amico, G., Fagioli, F., Ferrero, I., Locatelli, F., Maccario, R., Marazzi, M., Parolini, O., Pessina, A., Torre, M. L., Italian Mesenchymal Stem Cell Group, N., Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy, <<CURRENT PHARMACEUTICAL DESIGN>>, 2013; 19 (13): 2459-2473. [doi:10.2174/1381612811319130015] [http://hdl.handle.net/10807/92369]

Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy

Alessandri, Giulio;Parolini, Ornella;
2013

Abstract

Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.
Inglese
De Girolamo, L., Lucarelli, E., Alessandri, G., Avanzini, M. A., Bernardo, M. E., Biagi, E., Brini, A. T., D'amico, G., Fagioli, F., Ferrero, I., Locatelli, F., Maccario, R., Marazzi, M., Parolini, O., Pessina, A., Torre, M. L., Italian Mesenchymal Stem Cell Group, N., Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy, <<CURRENT PHARMACEUTICAL DESIGN>>, 2013; 19 (13): 2459-2473. [doi:10.2174/1381612811319130015] [http://hdl.handle.net/10807/92369]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/92369
Citazioni
  • ???jsp.display-item.citation.pmc??? 68
  • Scopus 131
  • ???jsp.display-item.citation.isi??? 111
social impact